Alphamab Oncology (HKG:9966)
Hong Kong
· Delayed Price · Currency is HKD 8.90
-0.08 (-0.89%)
May 23, 2025, 4:08 PM HKT
Alphamab Oncology Revenue
In the year 2024, Alphamab Oncology had annual revenue of 640.08M CNY with 192.58% growth. Alphamab Oncology had revenue of 466.52M in the half year ending December 31, 2024, with 311.85% growth.
Revenue
640.08M CNY
Revenue Growth
+192.58%
P/S Ratio
12.57
Revenue / Employee
1.52M CNY
Employees
420
Market Cap
8.56B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 32.53B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 32.81B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |